4.4 Article

Artesunate induces G2/M cell cycle arrest through autophagy induction in breast cancer cells

期刊

ANTI-CANCER DRUGS
卷 25, 期 6, 页码 652-662

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CAD.0000000000000089

关键词

artesunate; autophagy; breast cancer; cell cycle

资金

  1. National Natural Science Foundation of China [81101867, 81272542, 81200369, 81372443]
  2. China International Medical Foundation [CIMF-F-H001-057]
  3. Scientific Research Project of Jiangsu Provincial Bureau of Traditional Chinese Medicine [L213236]
  4. Medical Scientific Research Project of Jiangsu Provincial Bureau of Health [Z201206]
  5. Special Foundation of Wu Jieping Medical Foundation for Clinical Scientific Research [320.6753.1225, 320.6750.12242]
  6. Science and Education for Health Foundation of Suzhou for Youth [SWKQ1003, SWKQ1011]
  7. Science and Technology Project Foundation of Suzhou [SYS201112, SYSD2012137, SYS201335]

向作者/读者索取更多资源

We found that artesunate (ART) inhibited the growth of MCF-7 and MDA-MB-231 breast cancer cells. ART arrested the cell cycle in the G2/M phase, which was accompanied by an upregulation of p21. ART upregulated the expression of Beclin1, an initiator of autophagy (type II programmed cell death). In addition, ART stimulated the aggregation of LC3, which is considered to be a marker of autophagosome formation. We further verified the transformation of LC3 from type I into type II. 3-MA, a classical autophagy inhibitor, attenuated ART-induced autophagosome formation, cell growth repression, G2/M arrest, and p21 upregulation. Autophagy induction and p21 upregulation were also repressed by knockdown of Beclin1. Furthermore, ART sensitized breast cancer cells to the chemotherapeutic agent epirubicin through an autophagy-dependent cascade. Our study showed that ART induced autophagy in breast cancer cells and indicated that the anticancer effects of ART were exerted through an autophagy pathway. Moreover, ART sensitized breast cancer cells to epirubicin chemotherapy. Our results provide a basis for further development of ART as a novel therapeutic agent for the treatment of breast cancer. (C) 2014 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据